Ioxilan is a diagnostic contrast agent.[1] It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It was marketed in the US under the trade name Oxilan by Guerbet, L.L.C., but was discontinued in 2017.[2]
Clinical data | |
---|---|
Trade names | Oxilan |
AHFS/Drugs.com | FDA Professional Drug Information |
Routes of administration | intravenously |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | negligible |
Metabolism | none |
Elimination half-life | 2 hours |
Excretion | Mostly renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C18H24I3N3O8 |
Molar mass | 791.116 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
Ioxilan is an iodinated contrast agent.[2]